Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 12:12 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 865–888 of 10,853 matching trials from the live ClinicalTrials.gov search.

Filters: Columbus, Ohio Clear all

Conditions: Crohn Disease
Interventions: Capsule Endoscopy; Device
Lead sponsor: Medtronic - MITG; Industry
Eligibility: 18 Years and older
Enrollment: 187 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 24
States / cities: Mobile, Alabama • Scottsdale, Arizona • Jacksonville, Florida + 20 more

Conditions: Sepsis
Interventions: Vitamin C, Thiamine, Hydrocortisone, Vitamin C Placebo, Thiamine Placebo, Hydrocortisone Placebo; Drug
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older
Enrollment: 501 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 43
States / cities: Phoenix, Arizona • Tucson, Arizona • Los Angeles, California + 30 more

Conditions: Extensive Stage Lung Small Cell Cancer
Interventions: Ivonescimab 10 mg/kg, Ivonescimab 20 mg/kg; Drug
Lead sponsor: PrECOG, LLC.; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 13
States / cities: Miami, Florida • Chicago, Illinois • Baltimore, Maryland + 10 more

Conditions: Aortic Stenosis
Interventions: Lotus Valve System, CoreValve/Evolut R Transcatheter Aortic Valve Replacement System, LOTUS Edge Valve System; Device
Lead sponsor: Boston Scientific Corporation; Industry
Eligibility: Not listed
Enrollment: 1,425 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2021
U.S. locations: 49
States / cities: Phoenix, Arizona • Scottsdale, Arizona • La Jolla, California + 40 more

Conditions: Asthma
Interventions: GSK3511294 (Depemokimab), Placebo; Biological · Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 12 Years and older
Enrollment: 395 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 30
States / cities: Encinitas, California • Long Beach, California • Pasadena, California + 25 more

Conditions: Aspergillosis/Blood, Aspergillosis/Invasive
Interventions: micafungin, voriconazole; Drug
Lead sponsor: Astellas Pharma Inc; Industry
Eligibility: 2 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2007
U.S. locations: 44
States / cities: Birmingham, Alabama • Fountain Valley, California • Los Angeles, California + 41 more

Conditions: Epilepsy, Tonic-Clonic
Interventions: lamotrigine (LAMICTAL) extended-release, Placebo; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 13 Years and older
Enrollment: 153 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2008
U.S. locations: 64
States / cities: Anniston, Alabama • Birmingham, Alabama • Northport, Alabama + 56 more

Conditions: Idiopathic Pulmonary Fibrosis
Interventions: BI 1015550, Placebo; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 40 Years and older
Enrollment: 147 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 11
States / cities: Clearwater, Florida • Gainesville, Florida • Kansas City, Kansas + 8 more

Conditions: Hypercholesterolemia, Dyslipidemia
Interventions: ABT-335 and rosuvastatin calcium, ABT-335, rosuvastatin calcium; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 760 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 168
States / cities: Birmingham, Alabama • Huntsville, Alabama • Ozark, Alabama + 135 more

Conditions: Acute Heart Failure
Interventions: RLX030, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 6,600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 105
States / cities: Huntsville, Alabama • Montgomery, Alabama • Tucson, Arizona + 76 more

Conditions: Appendicitis
Interventions: Cefoxitin, Ertapenem, Moxifloxacin, Tigecycline, Ticarcillin-Clavulanic Acid; Metronidazole plus Cefazolin, Cefuroxime, Ceftriaxone, Cefotaxime, Ciprofloxacin, or Levofloxacin, Appendectomy; Drug · Procedure
Lead sponsor: University of Washington; Other
Eligibility: 18 Years and older
Enrollment: 1,552 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 25
States / cities: Sylmar, California • Torrance, California • Aurora, Colorado + 14 more

Conditions: Crohn's Disease
Interventions: Not listed
Lead sponsor: Emory University; Other
Eligibility: 5 Days to 16 Years
Enrollment: 1,813 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2020
U.S. locations: 25
States / cities: Los Angeles, California • San Francisco, California • Hartford, Connecticut + 20 more

Conditions: Carcinoid Tumor, Metastatic Carcinoid Tumor, Neuroendocrine Neoplasm
Interventions: Laboratory Biomarker Analysis, Nintedanib, Pharmacological Study, Quality-of-Life Assessment; Other · Drug
Lead sponsor: Roswell Park Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2022
U.S. locations: 2
States / cities: Buffalo, New York • Columbus, Ohio

Conditions: Heart Failure
Interventions: HNO Donor, Placebo; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 329 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 24
States / cities: Tucson, Arizona • Gainesville, Florida • Tampa, Florida + 16 more

Conditions: Chronic Lymphocytic Leukemia, Prolymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia
Interventions: Dinaciclib, Laboratory Biomarker Analysis, Ofatumumab, Pharmacological Study; Drug · Other · Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Meningitis, Cryptococcal, HIV Infections
Interventions: Fluconazole, Amphotericin B; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 330 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 28
States / cities: Los Angeles, California • Miami, Florida • Indianapolis, Indiana + 15 more

Conditions: Neoplasms
Interventions: Liposome-encapsulated SN38; Drug
Lead sponsor: INSYS Therapeutics Inc; Industry
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2010
U.S. locations: 3
States / cities: Tampa, Florida • Detroit, Michigan • Columbus, Ohio

Conditions: Head and Neck Neoplasms
Interventions: Pembrolizumab 200 mg, Radiotherapy 60 Gray, Radiotherapy 66 Gray, Radiotherapy 70 Gray, Cisplatin 100 mg/m^2; Biological · Radiation · Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 714 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2026
U.S. locations: 68
States / cities: La Jolla, California • Los Angeles, California • Newport Beach, California + 56 more

Conditions: Multiple Sclerosis
Interventions: ponesimod, teriflunomide; Drug
Lead sponsor: Actelion; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 1,133 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 10
States / cities: Carlsbad, California • Pomona, California • Denver, Colorado + 7 more

Conditions: Heart Failure
Interventions: Cardiac Resynchronization Therapy; Device
Lead sponsor: Medtronic Cardiac Rhythm and Heart Failure; Industry
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 3
States / cities: Des Moines, Iowa • Columbus, Ohio • Fairfield, Ohio

Conditions: Asthma
Interventions: ADVAIR 100/50mcg, ADVAIR 250/50mcg, ADVAIR 500/50mcg, FLOVENT 100mcg, FLOVENT 250mcg, FLOVENT 500mcg; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 12 Years and older
Enrollment: 11,751 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 350
States / cities: Athens, Alabama • Birmingham, Alabama • Florence, Alabama + 273 more

Conditions: Acute Myeloid Leukemia
Interventions: Cytarabine, Daunorubicin, Daunorubicin Hydrochloride, Pinometostat; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 14 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 3
States / cities: New Haven, Connecticut • Baltimore, Maryland • Columbus, Ohio

Conditions: Healthy Subject
Interventions: Educational Intervention, Survey Administration; Other
Lead sponsor: Ohio State University Comprehensive Cancer Center; Other
Eligibility: 18 Years to 25 Years · Male only
Enrollment: 150 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Hormone Receptor Positive Breast Carcinoma, HER2-negative Breast Cancer
Interventions: OP-1250; Drug
Lead sponsor: Olema Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 153 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 15
States / cities: Los Angeles, California • Aurora, Colorado • Deerfield Beach, Florida + 11 more

Search by objective public record fields.

Clinical Study Comparing PillCam® Crohn's Capsule Endoscopy to Ileocolonoscopy (IC) Plus MRE for Detection of Active CD in the Small Bowel and Colon in Subjects With Known CD and Mucosal Disease.

Vitamin C, Thiamine, and Steroids in Sepsis

Phase II Study of Platinum/Etoposide Plus Ivonescimab for Extensive-Stage Small Cell Lung Cancer

Safety and Efficacy Study of Lotus Valve for Transcatheter Aortic Valve Replacement

Placebo-controlled Efficacy and Safety Study of GSK3511294 (Depemokimab) in Participants With Severe Asthma With an Eosinophilic Phenotype

A Study to Evaluate the Effectiveness of Voriconazole + Micafungin Versus Voriconazole Alone for Invasive Aspergillosis

Study Evaluating LAMICTAL Extended-Release Therapy Added To Current Seizure Treatments In Patients With Primary Generalized Tonic-Clonic Seizures (PGTC) Seizures

A Study to Test How Taking BI 1015550 for 12 Weeks Affects Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF)

A Multicenter Study Comparing the Safety and Efficacy of ABT-335 and Rosuvastatin Calcium Combination Therapy to Monotherapy in Subjects With Dyslipidemia

Efficacy, Safety and Tolerability of Serelaxin When Added to Standard Therapy in AHF

The Comparison of Outcomes of Antibiotic Drugs and Appendectomy (CODA) Trial

Risk Stratification of Rapid Disease Progression in Children With Crohn's Disease

Nintedanib in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors

Evaluate the Safety and Efficacy of 48-Hour Infusions of HNO (Nitroxyl) Donor in Hospitalized Patients With Heart Failure

Ofatumumab and Dinaciclib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or B-Cell Prolymphocytic Leukemia

Comparison of Fluconazole and Amphotericin B in the Treatment of Brain Infections in Patients With AIDS

Liposome Encapsulated SN38 (LE-SN38) in Patients With Advanced Cancer

Study of Pembrolizumab Given Prior to Surgery and in Combination With Radiotherapy Given Post-surgery for Advanced Head and Neck Squamous Cell Carcinoma (MK-3475-689)

Oral Ponesimod Versus Teriflunomide In Relapsing MUltiple Sclerosis

Sensor Optimization of Cardiac Resynchronization Therapy Response

SAS115359: A 6-month Study to Assess the Safety and Benefit of Inhaled Fluticasone Propionate/Salmeterol Combination Compared With Inhaled Fluticasone Propionate in the Treatment of Adolescents and Adults (12 Years of Age and Older) With Asthma.

Pinometostat With Standard Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia and MLL Gene Rearrangement

Mobile Health Intervention in Increasing HPV Vaccine Coverage Among Young Adult Gay and Bisexual Men

A Dose Escalation/Expansion Study of Oral OP-1250 in Subjects With Advanced and/or Metastatic HR+, HER2- Breast Cancer